Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1998 1
1999 1
2001 2
2002 4
2003 2
2004 2
2005 4
2006 9
2007 1
2009 4
2010 3
2011 2
2012 3
2013 5
2014 6
2015 8
2016 5
2017 4
2018 4
2019 6
2020 7
2021 3
2022 5
2023 5
2024 9
2025 1
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free PMC article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis an …
N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A, Alfano F, Bigoni T, Mancini L, Mawass A, Baraldi F, Aljama C, Contoli M, Miravitlles M. Papi A, et al. Arch Bronconeumol. 2024 May;60(5):269-278. doi: 10.1016/j.arbres.2024.03.010. Epub 2024 Mar 18. Arch Bronconeumol. 2024. PMID: 38555190 Free article. English, Spanish.
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic mechanism in chronic respiratory conditions such as COPD and chronic bronchitis (CB). ...CONCLUSIONS: These findings prov …
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic me …
Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review.
Rogliani P, Manzetti GM, Gholamalishahi S, Cazzola M, Calzetta L. Rogliani P, et al. Int J Chron Obstruct Pulmon Dis. 2024 Oct 29;19:2347-2360. doi: 10.2147/COPD.S474512. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39493366 Free PMC article.
Mucus clearance is crucial for airway protection, and its dysfunction leads to chronic obstructive pulmonary disease (COPD) characterized by mucus hypersecretion (MHS) and impaired clearance. MUC5AC and MUC5B mucin proteins are key components of …
Mucus clearance is crucial for airway protection, and its dysfunction leads to chronic obstructive pulmonary disease …
Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.
Zhou Y, Wu F, Shi Z, Cao J, Tian J, Yao W, Wei L, Li F, Cai S, Shen Y, Wang Z, Zhang H, Chen Y, Fu Y, He Z, Chang C, Jiang Y, Chen S, Yang C, Yu S, Tian H, Cheng Q, Zhao Z, Ying Y, Zhou Y, Liu S, Deng Z, Huang P, Zhang Y, Luo X, Zhao H, Gui J, Lai W, Hu G, Liu C, Su L, Liu Z, Huang J, Zhao D, Zhong N, Ran P; China N-acetylcysteine in Mild-to-moderate COPD Study Group. Zhou Y, et al. Nat Commun. 2024 Sep 30;15(1):8468. doi: 10.1038/s41467-024-51079-1. Nat Commun. 2024. PMID: 39349461 Free PMC article. Clinical Trial.
Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) is limited. The efficacy of N-acetylcysteine (an antioxidant and mucolytic agent) for patients with mild-to-moderate COPD …
Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) …
Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective.
Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Santus P, et al. J Clin Med. 2024 Jul 15;13(14):4127. doi: 10.3390/jcm13144127. J Clin Med. 2024. PMID: 39064168 Free PMC article. Review.
These properties have sparked interest in its potential for treating chronic lung diseases, including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE), cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF), …
These properties have sparked interest in its potential for treating chronic lung diseases, including chronic obstructive …
Oxidative stress-based therapeutics in COPD.
Barnes PJ. Barnes PJ. Redox Biol. 2020 Jun;33:101544. doi: 10.1016/j.redox.2020.101544. Epub 2020 Apr 20. Redox Biol. 2020. PMID: 32336666 Free PMC article. Review.
Increased systemic oxidative stress may exacerbate comorbidities and contribute to skeletal muscle weakness. Oxidative stress amplifies chronic inflammation, stimulates fibrosis and emphysema, causes corticosteroid resistance, accelerates lung aging, causes DNA dama …
Increased systemic oxidative stress may exacerbate comorbidities and contribute to skeletal muscle weakness. Oxidative stress amplifi …
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Rogliani P, et al. Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y. Respir Res. 2019. PMID: 31133026 Free PMC article.
Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive pulmonary disease (COPD), and the recent publication of Reducing Exacerbations and Symptoms by Treatmen …
Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstruc …
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Ohnishi H, et al. Respir Investig. 2024 Nov;62(6):1168-1175. doi: 10.1016/j.resinv.2024.10.004. Epub 2024 Oct 15. Respir Investig. 2024. PMID: 39413571
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis or exacerbations of COPD have been reported. ...RESULTS: Twenty-three reports with ambrox …
BACKGROUND: The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COP …
N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM. Sanguinetti CM. Multidiscip Respir Med. 2016 Feb 3;11:8. doi: 10.1186/s40248-016-0039-2. eCollection 2015. Multidiscip Respir Med. 2016. PMID: 26855777 Free PMC article. Review.
Thus an exogenous supplementation of antioxidant compounds is mandatory to at least partially counteract the oxidative stress. For this purpose N-acetylcysteine has great potentialities due to its capacity of directly contrasting oxidants with its free thiols, and t …
Thus an exogenous supplementation of antioxidant compounds is mandatory to at least partially counteract the oxidative stress. For this purp …
The precision medicine strategy to treat COPD pulmonary traits in clinical practice: The role of N-acetylcysteine.
Scioscia G, Baraldi F, Bigoni T, Papi A, Vatrella A, Micheletto C, Foschino Barbaro MP. Scioscia G, et al. Respir Med. 2024 Dec;235:107865. doi: 10.1016/j.rmed.2024.107865. Epub 2024 Nov 15. Respir Med. 2024. PMID: 39549856 Review.
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition and a leading cause of physical decline and death. ...N-acetylcysteine (NAC), a widely used mucolytic agent, might be a major player in this strategy. ...
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition and a leading cause of physi …
106 results